Publication | Closed Access

The development of technetium-99m-labelled interleukin-2: A new radiopharmaceutical for the In vivo detection of mononuclear cell infiltrates in immune-mediated diseases

InflammationImmune-mediated DiseasesVivo DetectionAutoimmune DiseaseMedicineT-regulatory CellImmunologyPathologyImmune SurveillanceAutoimmunityTechnetium-99m-labelled Interleukin-2Cellular Immune ResponseImmune SystemImmunotherapyImmunological Biomarkers